C
아리바이오랩
261780KOSDAQ42.5 / 100
Reference Date: 2026-10-23
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Chabaksin Research Institute is a biotech company specializing in the development of vaccines and immunotherapies using advanced technologies such as virus-like particles (VLP), liposomes, and immune checkpoint inhibitors (ICI). The company focuses on immunological research, antigen presentation, and apoptosis-related mechanisms to develop new drugs for infectious diseases and cancer.
Number of Employees
49people
Average Salary
63.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
9.49Industry Average 1.200.0Point
7.9x industry avg (risky)
ROE
-81.07Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
14.65Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼15.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼52.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -39.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (52%)
Current 3,885Won52-week high 5,70052-week low 1,857
1-month return2.0Point
1m -3.96% (slight drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral증권발행결과(자율공시)2026-10-16
- Neutral주요사항보고서(자기전환사채매도결정)2026-10-16
- Neutral투자판단관련주요경영사항 (경영지배인 사임)2026-10-06
- Neutral주권관련사채권의취득결정2026-09-29
- Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-09-28